Randomized trial explores gut microbiota's influence on drug metabolism in personalized medicine, suggesting improved outcomes.
The gut microbiota plays an important role in drug metabolism and pharmacokinetics by influencing drug absorption, bioavailability, and toxicity through various microbial enzymatic reactions.[1–3]. Increasing evidence suggests that microbiota-mediated drug metabolism contributes significantly to interindividual variability in therapeutic response and adverse drug reactions.[4,5] Gut microorganisms can activate prodrugs, inactivate therapeutic agents, generate toxic metabolites, and regulate host metabolic enzymes.[6,7] Advances in pharmacomicrobiomics and microbiome research have highlighted the importance of integrating microbial profiling into personalized medicine.[8,9] Understanding drug–microbiota interactions may improve therapeutic outcomes, minimize adverse effects, and facilitate precision-based pharmacotherapy.[10]
No takes yet. Share an insight, caveat, or question.
Dr. Nidhi Chauhan1*, Mr. Ghanchi Husen Hamidbhai2*, Mr. Vijay Oza3, Mr. Zarakh Saad Saeed Hashan4, Mrs. Niharika Patel5 (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: